


A monthly report summarizing the Life Science transactions and trends in Washington State.


Washington State Transactions

Washington State Transactions by Industry



*As of February 28th, 2017

Deals by sector



Highlights

February Highlights

- *Faraday Pharmaceuticals*, a biopharmaceutical company developing elemental reducing agents to improve outcomes for patients, raised \$28.9M in equity financing.
- *Nativis*, a clinical- stage bio-electronics company developing technology that specifically regulates metabolic pathways, raised \$9.3M in equity financing.
- The *Governor’s Life Science & Global Health Advisory Council Report* was released and reported that Washington’s life science industry is at significant risk as there has been a steady decline in jobs since 2011, despite being among the best in the nation for attracting federally funded research.

This report is prepared by Kayla Young, PhD. Questions or comments? Contact kayla@lifesciencewa.org.

**The data in this report are compiled from publicly disclosed information and is not independently verified by Life Science Washington.

Washington Life Science Transactions 2017

Date	Company	Type	Amount
01/01/17	Adaptive Biotechnologies	Grant/SBIR	\$519,759
01/01/17	Group Health Cooperative	Grant	\$249,179
01/01/17	Lumithera, Inc	Grant/SBIR	\$140,000
01/02/17	PAI Life Science	Grant/SBIR	\$1,380,664
01/05/17	Aqueduct Critical Care, Inc	Debt	\$2,010,000
01/05/17	PVP Biologics	Partnership	\$35,000,000
01/12/17	OtoNexus Medical Technologies	Equity	\$7,849,073
01/13/17	Vicis, Inc	Debt	\$4,100,000
01/25/17	KenSci	Series A	\$8,500,000
01/31/17	Kineta	Equity and Debt	\$250,000
02/08/17	Vesiflo, Inc	Equity	\$2,403,492
02/07/17	Visualant Inc	Other	\$218,751
02/09/17	Visualant Inc	Equity	\$106,666
02/15/17	Omage Labs Inc	Equity and Debt	\$25,000
02/21/17	Cyrus Biotechnology	Equity	\$1,040,000
02/21/17	Farady Pharmaceuticals	Equity	\$28,949,480
02/23/17	Clocktree Systems Inc	Debt	\$600,000
02/23/17	Nativis, Inc	Equity	\$9,368,795
02/27/17	DMD Therapeutics	Grant	\$400,000
02/28/17	Kineta, Inc.	Debt	\$47,250
02/28/17	Kineta, Inc.	Debt	\$5,000,000
2017 Running Total			\$108,158,109

Don't see a transaction listed?

Contact Kayla Young at

kayla@lifesciencewa.org

Washington Life Science Transactions 2016

Date	Company	Type	Amount	Date	Company	Type	Amount
01/07/16	NanoString Technologies	Unknown	\$22,000,000	06/13/16	Alpine Immune Sciences	Equity	\$48,000,000
01/11/16	Spiral Genetics	Unknown	\$50,000	06/20/16	Kineta	Debt	\$1,752,688
01/12/16	Blaze Bioscience	Debt	\$991,000	06/22/16	Marina Biotech	Debt	\$300,000
01/14/16	Stemgenics	Equity	\$930,000	06/24/16	TwinStrand Biosciences	Debt	\$1,938,964
01/20/16	Vicis	Seed	\$8,000,000	07/05/16	Revalerio Corp	Equity	\$13,999,912
01/25/16	Clario Medical Imaging	Equity	\$185,000	07/14/16	Magnolia Medical Technologies	Series B	\$13,757,109
02/02/16	Oricula Therapeutics	Grant	\$2,060,000	07/19/16	Joylux	Equity	\$2,000,000
02/02/16	ID Genomics	Equity	\$50,000	07/26/16	Just Biotherapeutics	Series A	\$14,000,000
02/11/16	M3 Biotechnology	Equity	\$10,000,000	08/04/16	98point6	Equity	\$11,000,000
02/11/16	Spiral Genetics	Unknown	\$50,000	08/05/16	Mirabilis Medica	Debt	\$5,000,000
02/16/16	Physio-Control	Acquisition	\$1,280,000,000	08/09/16	CSATS	Equity	\$3,283,516
02/16/16	KPI Therapeutics	Debt	\$50,500	08/09/16	SpringStar	Grant	\$1,500,000
02/17/16	GlycoStasis	Acquisition	undisclosed	08/10/16	Ave Maria Biotechnology	Equity	\$100,000
02/23/16	Cytodyn	Equity	\$30,574,665	08/17/16	Kineta IO, LLC	Equity	\$238,422
02/24/16	Ave Maria Biotechnology	Equity	\$40,000	08/17/16	Kineta One, LLC	Debt	\$125,000
02/29/16	VitalWare	Series A	undisclosed	08/17/16	Vie Diagnostics	Grant	\$225,000
02/29/16	NanoString Technologies	Partnership	\$24,000,000	08/19/16	Nexgenia	Equity	\$1,859,887
03/03/16	LabConnect	Venture Equity	\$4,000,000	08/23/16	Benaroya Research Institute	Grant	\$8,000,000
03/11/16	Allen Institute for Brain Science	Contract	\$18,700,000	08/24/16	Briotech	Equity	\$250,000
03/16/16	Ave Maria Biotechnology	Equity	\$350,000	08/29/16	Impel Neuropharma	Debt	\$1,090,000
03/17/16	Act X	Unknown	\$308,810	08/29/16	Navisonics	Debt	\$335,000
03/22/16	Seattle Children's Research Institute	Grant	\$1,000,000	08/30/16	KinDex Pharmaceuticals	Debt	\$327,274
03/22/16	Breast Microseed	Debt	\$100,000	09/16/16	Sound Pharmaceuticals	Debt	\$3,800,000
03/23/16	Frazier Healthcare Partners	Fund	\$525,000,000	09/16/16	Cocrystal Discovery	Equity	\$4,008,201
03/23/16	University of Washington	Grant	\$250,000	09/20/16	Immune Design	Public Offering	\$30,300,000
03/24/16	The Paul G. Allen Frontiers Group	Fund	\$100,000,000	09/26/16	Ario	Equity	\$1,035,000
04/06/16	Cyrus Biotechnology	Debt	\$535,000	09/28/16	Verda Bio	Equity	\$545,000
04/06/16	2Morrow	Debt	\$325,000	09/29/16	PotaVida	Equity	\$275,000
04/07/16	Medstreaming LLC	Equity	\$12,200,000	10/06/16	Infectious Disease Research Institute	Grant	\$491,000
04/07/16	Prevensio, Inc	Debt	\$675,000	10/13/16	Feminina Group	Debt	\$77,500
04/08/16	Medstreaming LLC	Equity	\$2,500,000	10/13/16	Vicis	Debt	\$3,955,000
04/12/16	Silverback Therapeutics	Equity	\$10,000,000	10/18/16	Impel Neuropharma	Debt	\$80,000
04/14/16	Vicis	Series A	\$4,000,000	10/18/16	Sightlight Surgical	Series A	\$10,000,000
04/18/16	Juno Therapeutics	Partnership	\$50,000,000	10/18/16	Infectious Disease Research Institute	Partnership	\$15,000,000
04/23/16	ID Genomics	Grant	\$3,000,000	10/18/16	Deep Cell Industries	Equity	\$25,000
04/27/16	Cardiac Insight	Debt	\$2,505,524	11/01/16	Immusoft Corp	Series A	\$2,739,999
04/29/16	Ave Maria Biotechnology	Equity	\$2,200,000	11/07/16	Act X	Equity	\$1,900,646
05/05/16	Kineta	Award	\$7,200,000	11/16/16	Cyrus Biotechnology	Equity	\$490,000
05/10/16	Aqueduct Critical Care	Equity	\$3,067,177	11/18/16	Invio, Inc	Angel	\$160,000
05/10/16	Spiral Genetics	Unknown	\$50,000	12/01/16	Washington State University	Grant	\$50,000
05/11/16	Cytodyn	Equity	\$4,301,500	12/01/16	Impel Neuropharma	Series C	\$22,297,064
05/11/16	Mental Health Data Services	Equity	\$333,333	12/05/16	Nohla Therapeutics	Series A	\$11,999,999
05/13/16	Ave Maria Biotechnology	Equity	\$50,000	12/05/16	KPI Therapeutics	Equity	\$18,000
05/17/16	PhaseRx	IPO	\$18,500,000	12/06/16	Cardiac Insight	Series C	\$1,000,000
05/20/16	Haverhill Genetics	Debt	\$125,000	12/08/16	ApoGen Biotechnologies, Inc	Series A	\$3,815,892
05/24/16	Vicis	Equity	\$6,000,000	12/08/16	Integrated Diagnostics	Equity	\$6,099,999
05/25/16	Kineta Three, LLC	Equity	\$760,778	12/13/16	Ave Maria Biotechnology	Equity	\$225,000
05/26/16	Litesprite	Debt	\$50,000	12/20/16	Briotech	Equity	\$100,000
05/31/16	Kineta Two, LLC	Equity	\$67,275	12/21/16	C3J Therapeutics	Equity	\$18,999,999
06/02/16	Mirabilis Medica	Debt	\$2,232,833	12/28/16	Valant Medical Solutions	Equity	\$7,500,000
06/09/16	Ave Maria Biotechnology	Equity	\$100,000				
06/09/16	Cadence Biomedical	Debt	\$80,000				
				2016 Total			\$2,435,649,466

Don't see a transaction listed?

Contact Kayla Young at

kayla@lifesciencewa.org

This report is prepared by Wendy Yang, PhD, and Kayla Young, PhD. Questions or comments? Contact kayla@lifesciencewa.org.

**The data in this report are compiled from publicly disclosed information and is not independently verified by Life Science Washington.